{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,4,28]],"date-time":"2026-04-28T23:12:24Z","timestamp":1777417944556,"version":"3.51.4"},"reference-count":26,"publisher":"Wiley","issue":"5","license":[{"start":{"date-parts":[[2018,5,30]],"date-time":"2018-05-30T00:00:00Z","timestamp":1527638400000},"content-version":"vor","delay-in-days":29,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"funder":[{"name":"Astellas Pharma, Inc. under the co-development partnership with Kyowa Hakko Kirin Co."}],"content-domain":{"domain":["onlinelibrary.wiley.com"],"crossmark-restriction":true},"short-container-title":["Biopharm &amp; Drug Disp"],"published-print":{"date-parts":[[2018,5]]},"abstract":"<jats:title>Abstract<\/jats:title><jats:p>This study evaluated the pharmacokinetics (PK), efficacy, safety, and tolerability of bleselumab \u2013 a fully\u2010human anti\u2010CD40 monoclonal recombinant IgG4. Patients with moderate\u2010to\u2010severe psoriasis were randomized on day 1 to receive bleselumab or placebo on days 1, 15 and 29 in a dose\u2010escalation of bleselumab at 0.1, 0.3, 1.0 or 3.0\u00a0mg\/kg. The safety\u2010analysis set (SAF) and full\u2010analysis set (FAS) included all patients who received bleselumab or placebo, and the PK\u2010analysis set (PKAS) included patients in the SAF with \u22651 quantifiable serum bleselumab concentration. Serial blood samples were collected after each dose, and the bleselumab serum concentration was measured. After each dose, the area\u2010under\u2010the\u2010concentration\u2013time curve over 336\u00a0hours (AUC<jats:sub>336<\/jats:sub>) and the maximum serum concentration (C<jats:sub>max<\/jats:sub>), and dose proportionality of AUC<jats:sub>336<\/jats:sub> and C<jats:sub>max<\/jats:sub> were determined. The psoriasis area and severity index (PASI) score, the physician static global assessment (PSGA) score, the percentage body surface area (%BSA) affected with psoriasis, adverse events and laboratory parameters were assessed. Sixty patients were randomized and included in the SAF\/FAS (bleselumab, <jats:italic>n<\/jats:italic>\u00a0=\u00a049; placebo, <jats:italic>n<\/jats:italic>\u00a0=\u00a011); 48 formed the PKAS. Bleselumab C<jats:sub>max<\/jats:sub> and AUC<jats:sub>336<\/jats:sub> were more than dose proportional in the range 0.1\u20133.0\u00a0mg\/kg, suggesting nonlinear PK after single\/multiple doses. No clinically significant infusion reactions, cytokine\u2010release syndrome, or thromboembolic events were reported. Bleselumab did not improve the PASI scores, PSGA scores, or %BSA versus placebo. Transient elevation of alanine aminotransferase and aspartate aminotransferase levels by &gt;3 \u00d7 upper limit of normal were observed in four (8.2%) and two (4.1%) patients, respectively, in the 1.0 or 3.0\u00a0mg\/kg groups. Patients with liver function test increases had no concurrent changes in bilirubin. Bleselumab demonstrated nonlinear PK after single and multiple doses, with few adverse reactions.<\/jats:p>","DOI":"10.1002\/bdd.2130","type":"journal-article","created":{"date-parts":[[2018,4,21]],"date-time":"2018-04-21T09:44:20Z","timestamp":1524303860000},"page":"245-255","update-policy":"https:\/\/doi.org\/10.1002\/crossmark_policy","source":"Crossref","is-referenced-by-count":30,"title":["Randomized, controlled study of bleselumab (ASKP1240) pharmacokinetics and safety in patients with moderate\u2010to\u2010severe plaque psoriasis"],"prefix":"10.1002","volume":"39","author":[{"given":"Mysore S.","family":"Anil Kumar","sequence":"first","affiliation":[{"name":"Astellas Pharma, Inc.  Northbrook Illinois, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-9557-3642","authenticated-orcid":false,"given":"Kim","family":"Papp","sequence":"additional","affiliation":[{"name":"K Papp Clinical Research and Probity Medical Research  Waterloo Canada"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ryo","family":"Tainaka","sequence":"additional","affiliation":[{"name":"Astellas Pharma, Inc.  Tokyo Japan"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Udaya","family":"Valluri","sequence":"additional","affiliation":[{"name":"Astellas Pharma, Inc.  Northbrook Illinois, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Xuegong","family":"Wang","sequence":"additional","affiliation":[{"name":"Astellas Pharma, Inc.  Northbrook Illinois, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Tong","family":"Zhu","sequence":"additional","affiliation":[{"name":"Astellas Pharma, Inc.  Northbrook Illinois, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Christian","family":"Schwabe","sequence":"additional","affiliation":[{"name":"Auckland Clinical Studies Ltd  Auckland New Zealand"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"311","published-online":{"date-parts":[[2018,5,30]]},"reference":[{"key":"e_1_2_10_2_1","doi-asserted-by":"publisher","DOI":"10.1007\/s00228-017-2362-8"},{"key":"e_1_2_10_3_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1600-6143.2009.02693.x"},{"key":"e_1_2_10_4_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1365-2141.2012.09251.x"},{"key":"e_1_2_10_5_1","doi-asserted-by":"publisher","DOI":"10.1038\/cmi.2012.15"},{"key":"e_1_2_10_6_1","doi-asserted-by":"publisher","DOI":"10.1111\/jdv.13150"},{"key":"e_1_2_10_7_1","doi-asserted-by":"publisher","DOI":"10.1002\/psp4.41"},{"key":"e_1_2_10_8_1","doi-asserted-by":"publisher","DOI":"10.1111\/ajt.12082"},{"key":"e_1_2_10_9_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.amepre.2014.02.012"},{"key":"e_1_2_10_10_1","doi-asserted-by":"publisher","DOI":"10.1089\/153623002753632084"},{"key":"e_1_2_10_11_1","doi-asserted-by":"publisher","DOI":"10.1038\/sj.gene.6364375"},{"key":"e_1_2_10_12_1","doi-asserted-by":"publisher","DOI":"10.3109\/08916934.2016.1166214"},{"key":"e_1_2_10_13_1","unstructured":"Kernstock R.(2010).Bioanalytical Validation Report IC\u20102009\u2013002. Validation of an analytical method for the screening confirmation and titer for the presence of anti\u2010ASKP1240 antibodies in human serum using electrochemiluminescence detection. Skokie IL USA."},{"key":"e_1_2_10_14_1","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2016.00021"},{"key":"e_1_2_10_15_1","doi-asserted-by":"publisher","DOI":"10.1097\/00007890-199601150-00002"},{"key":"e_1_2_10_16_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1600-6143.2006.01259.x"},{"key":"e_1_2_10_17_1","doi-asserted-by":"publisher","DOI":"10.1111\/ajt.12678"},{"key":"e_1_2_10_18_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1600-6143.2012.04014.x"},{"key":"e_1_2_10_19_1","doi-asserted-by":"publisher","DOI":"10.2310\/7750.2011.10066"},{"key":"e_1_2_10_20_1","doi-asserted-by":"publisher","DOI":"10.1038\/jid.2012.339"},{"key":"e_1_2_10_21_1","doi-asserted-by":"publisher","DOI":"10.1002\/path.1581"},{"key":"e_1_2_10_22_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.smim.2009.05.012"},{"key":"e_1_2_10_23_1","doi-asserted-by":"publisher","DOI":"10.2340\/00015555-1273"},{"key":"e_1_2_10_24_1","doi-asserted-by":"publisher","DOI":"10.1038\/nbt1303"},{"key":"e_1_2_10_25_1","doi-asserted-by":"publisher","DOI":"10.1097\/TP.0000000000000236"},{"key":"e_1_2_10_26_1","doi-asserted-by":"publisher","DOI":"10.1046\/j.1087-0024.2003.09102.x"},{"key":"e_1_2_10_27_1","volume-title":"Global Report on Psoriasis","author":"World Health Organization","year":"2016"}],"container-title":["Biopharmaceutics &amp; Drug Disposition"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.wiley.com\/onlinelibrary\/tdm\/v1\/articles\/10.1002%2Fbdd.2130","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1002\/bdd.2130","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,9,16]],"date-time":"2023-09-16T12:11:29Z","timestamp":1694866289000},"score":1,"resource":{"primary":{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/10.1002\/bdd.2130"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2018,5]]},"references-count":26,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2018,5]]}},"alternative-id":["10.1002\/bdd.2130"],"URL":"https:\/\/doi.org\/10.1002\/bdd.2130","archive":["Portico"],"relation":{},"ISSN":["0142-2782","1099-081X"],"issn-type":[{"value":"0142-2782","type":"print"},{"value":"1099-081X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2018,5]]},"assertion":[{"value":"2017-12-13","order":0,"name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2018-04-15","order":1,"name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}},{"value":"2018-05-30","order":2,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}]}}